Arbutus Biopharma Corporation (ABUS)
| Market Cap | 815.83M +18.0% |
| Revenue (ttm) | 191.45M +2,889.9% |
| Net Income | 160.72M |
| EPS | 0.84 |
| Shares Out | 197.54M |
| PE Ratio | 4.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,226 |
| Open | 4.110 |
| Previous Close | 4.170 |
| Day's Range | 4.060 - 4.146 |
| 52-Week Range | 3.040 - 5.100 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 7.10 (+71.91%) |
| Earnings Date | May 13, 2026 |
About ABUS
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inh... [Read more]
Financial Performance
In 2025, Arbutus Biopharma's revenue was $14.08 million, an increase of 128.21% compared to the previous year's $6.17 million. Losses were -$33.50 million, -52.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price target is $7.1, which is an increase of 71.91% from the latest price.
News
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
Arbutus Biopharma granted Fast Track designation for imdusiran
Arbutus Biopharma (ABUS) announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABU...
Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies
Jefferies lowered the firm’s price target on Arbutus Biopharma (ABUS) to $5.50 from $7 and keeps a Buy rating on the shares. The key question post the Moderna (MRNA) settlement…
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?
Moderna ($MRNA) stock is up by almost 9% in early trading on Wednesday after the vaccine maker announced it had settled patent litigation with Arbutus Biopharma ($ABUS) and Genevant Sciences.
Unusually active option classes on open March 4th
Unusual total active option classes on open include: Arbutus Biopharma (ABUS), Abercrombie & Fitch (ANF), Teck Resources (TECK), Ford (F), Plug Power (PLUG), Devon Energy (DVN), Poet Technologies (POE...
Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement
As previously reported, Moderna (MRNA) announced that it has entered into a settlement agreement with Arbutus Biopharma (ABUS) and Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), resolving...
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its ...
Genevant, Arbutus announce $2.25B global settlement with Moderna
Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), and Arbutus Biopharma Corporation (ABUS), announced that they have entered into a $2.25 billion global settlement with Moderna (MRNA) to res...
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Cir...
Arbutus faces higher bar to argue infringement by Moderna, says Jefferies
Jefferies analyst Dennis Ding notes that Judge Wolson issued summary judgment on three matters in a patent fight between Arbutus Biopharma (ABUS) and Moderna (MRNA). While the analyst says two…
Moderna reverses lower after court issues memo in patent fight with Arbutus
Shares of Arbutus Biopharma (ABUS) are up 10% in afternoon trading while those of Moderna (MRNA) are now down 3%.
Moderna rises after Delaware court issues memo in patent fight with Arbutus
In a memorandum posted to the site of the U.S. District Court for the District of Delaware, a judge wrote in part: “In this case, Arbutus Biopharma (ABUS) Corp. and…
European Patent Office ruling ‘clear win’ for Moderna, says Citi
Citi says the European Patent Office Board of Appeal invalidated a key Arbutus Biopharma (ABUS) delivery technology patent, which is a “clear win” for Moderna (MRNA). The invalidation neutralizes a…
Arbutus says European patent revoked by European Patent Office
Arbutus Biopharma (ABUS) disclosed on Friday that the Board of Appeal of the European Patent Office revoked the company’s European patent EP 2279254. “This verbal decision, provided without reasons, w...
Arbutus Biopharma loses patent appeal in Europe, Bloomberg reports
The European Patent Office appeals board has revoked one of Arbutus Biopharma’s (ABUS) patents, which is likely to affect its case against Moderna (MRNA) in Switzerland and one Unified Patent…
Arbutus Biopharma reports Q3 EPS (4c), consensus (5c)
Reports Q3 revenue $529k, consensus $1.31M. “The strength of our third quarter performance reflects our disciplined focus on executing strategic priorities,” said Lindsay Androski, President and CEO o...
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioN...
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Pos...
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China